Aptus Pharma ke H1 FY2027 numbers kaafi solid aaye hain. Revenue badhkar **₹48.92 Crore** aur profit **₹5.08 Crore** par pahunch gaya hai. Saath hi, company **₹44.88 Crore** ka preferential issue bhi la rahi hai, bas ab BSE se green signal ka intezaar hai.
Performance mein bada uchhal
Aptus Pharma ne H1 (ending 30 September 2026) ke jo results dikhaye hain, woh kaafi tagde hain. Pichle saal ke ₹14.38 Crore ke revenue ke mukable, is baar revenue ₹48.92 Crore raha. Wahi, profit after tax (PAT) ₹1.75 Crore se badhkar ₹5.08 Crore ho gaya hai. Yaad rahe, ye numbers May 2026 ke 3:2 bonus issue ke adjust hone ke baad ke hain.
Capital infusion ka kya scene hai?
Company ab 1,602,870 shares ₹280 ke price par issue kar rahi hai, jisse total ₹44.88 Crore ka fund jutaya jayega. Ye paisa company ke infrastructure aur distribution network ko badhane ke liye hai taaki woh India mein apni reach 46% tak le ja sakein.
Investors ke liye kya hai important?
Filhal ye deal abhi complete nahi hui hai. AGM mein shareholders ne haan bol diya hai, lekin BSE se abhi in-principle approval aana baaki hai. Jab tak ye approval nahi milta aur paisa company ke account mein nahi aata, tab tak ye sirf ek proposal hai.
Risk kya hai?
Sabse bada risk regulatory delay ka hai. Agar BSE se approval aane mein der hui, toh company ke March 2027 wale expansion goals par asar pad sakta hai. Isliye, BSE ki official update par apni nazar banaye rakhein.